Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on October 30, 2019. The report details the commencement of an underwritten public offering of the Company's common stock pursuant to an effective shelf registration statement (File No. 333-220632) declared effective on October 10, 2017.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to announce a corporate event.
Material Changes
The material event reported is the initiation of a public offering of common stock. No financial performance changes or operational shifts are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) for further details on the offering but does not include specific management commentary, future guidance, risk factors, or contingencies within the text of the 8-K itself.
Investor Verification Checklist
- Verify the final terms of the underwritten public offering (price per share, number of shares, and total proceeds) in the accompanying press release or prospectus supplement.
- Confirm the identity of the underwriters and any over-allotment options.
- Review the Company's most recent 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the completion or termination of the offering.